Safety, Pharmacokinetics and Efficacy Study of MP-214 in Patients With Schizophrenia

Sponsor
Tanabe Pharma Corporation
Study ID
NCT00862992
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
20 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study is to assess the safety, pharmacokinetics and efficacy of 3 fixed doses of MP-214 orally administered once daily to patients with schizophrenia. MP-214 tablets will be administered to patients starting at an initial dose, followed by up-titration to a fixed dose (low, medium or high) for 14 days.

Key Dates

Start date
Apr 30, 2008
Status verified
Dec 2025
Primary completion
Sep 30, 2009
Completion
Sep 30, 2009

Study Design

Enrollment
34 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: 1
  • Experimental: 2
  • Experimental: 3

Primary Outcome Measure

Number of Participants With Adverse Event and Adverse Drug Reaction [ Time Frame: Up to 7 weeks ]

Related Studies